Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis

Multiple Sclerosis

Volumn 22, Issue 8, 2016, Pages 1080-1085

  Simula, Sakari ^a   Laitinen, Tomi ^b   Laitinen, Tiina M ^b   Tarkiainen, Tuula ^a   Hartikainen, Päivi ^b   Hartikainen, Juha E K ^b  

^a MIKKELI CENTRAL HOSPITAL   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cardiac autonomic regulation; fingolimod; heart rate variability; multiple sclerosis

Indexed keywords

FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT;

ADRENERGIC STIMULATION; ADULT; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; DRUG EFFECT; ELECTROCARDIOGRAM; FEMALE; HEART AUTOMATICITY; HEART RATE VARIABILITY; HUMAN; MALE; MULTIPLE SCLEROSIS; PARASYMPATHETIC INNERVATION; PROSPECTIVE STUDY; RR INTERVAL; SEX DIFFERENCE; VAGUS NERVE; ADRENERGIC SYSTEM; AMBULATORY ELECTROCARDIOGRAPHY; CHOLINERGIC SYSTEM; DRUG EFFECTS; HEART; HEART RATE; INNERVATION; MIDDLE AGED; PATHOPHYSIOLOGY; SEX FACTOR; TIME FACTOR; TREATMENT OUTCOME; CARDIAC AUTONOMIC REGULATION; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; COMORBIDITY; DIASTOLIC BLOOD PRESSURE; ELECTROCARDIOGRAPHY; EXPANDED DISABILITY STATUS SCALE; GENDER; SYMPATHOVAGAL BALANCE; SYSTOLIC BLOOD PRESSURE;

ADULT; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FINGOLIMOD HYDROCHLORIDE; HEART; HEART RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PARASYMPATHETIC NERVOUS SYSTEM; PROSPECTIVE STUDIES; SEX FACTORS; SYMPATHETIC NERVOUS SYSTEM; TIME FACTORS; TREATMENT OUTCOME;

EID: 84978150680     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515604384     Document Type: Article

References (28)

1. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.
2. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
3. Chun J, Hartung HP,. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010; 33: 91-101.
4. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296: 346-349.
5. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427: 355-360.
6. Mehling M, Johnson TA, Antel J, et al. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 2011; 76: S20-S27.
7. Brinkmann V,. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007; 115: 84-105.
8. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010; 9: 883-897.
9. Mizugishi K, Yamashita T, Olivera A, et al. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol 2005; 25: 11113-11121.
10. Camm J, Hla T, Bakshi R, et al. Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications. Am Heart J 2014; 168: 632-634.
11. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: Standards of measurement, physiological interpretation and clinical use. Circulation 1996; 93: 1043-1065.
12. Hartikainen J, Malik M, Staunton A, et al. Distinction between arrhythmic and nonarrhythmic death after acute myocardial infarction based on heart rate variability, signal-averaged electrocardiogram, ventricular arrhythmias and left ventricular ejection fraction. J Am Coll Cardiol 1996; 28: 296-304.
13. Kleiger RE, Miller JP, Bigger JTJ, et al. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59: 256-262.
14. Tsuji H, Larson MG, Venditti FJ, et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation 1996; 94: 2850-2855.
15. Simula S, Laitinen T, Laitinen TM, et al. Effects of three months fingolimod therapy on heart rate. J Neuroimmune Pharmacol 2015; doi 10.1007/s11481-015-9619-8
16. Monfredi O, Lyashkov AE, Johnsen AB, et al. Biophysical characterization of the underappreciated and important relationship between heart rate variability and heart rate. Hypertension 2014; 64: 1334-1343.
17. Pomeranz M, Macaulay RJB, Caudill MA, et al. Assessment of autonomic function in humans by heart rate spectral analysis. Am J Physiol 1985; 248: H151-H153.
18. Akselrod S, Gordon D, Ubel FA, et al. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat to beat cardiovascular control. Science 1981; 213: 220-222.
19. Koyrakh L, Roman MI, Brinkmann V, et al. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant 2005; 5: 529-536.
20. Rossi S, Rocchi C, Struder V, et al. The autonomic balance predicts cardiac responses after the first dose of fingolimod. Mult Scler 2015; 21: 206-216.
21. Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomized, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 16: 545-556.
22. Laroni A, Brogi D, Morra VB, et al. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. BMC Neurol 2014; 14: 65. doi: 10.1186/1471-2377-14-65
23. Murakami A, Takasugi H, Ohnuma S, et al. Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: investigation based on a new S1P3 receptor antagonist. Mol Pharmacol 2010; 77: 704-713.
24. Malik M, Camm AJ,. Components of heart rate variability-what they really mean and what we really measure. Am J Cardiol 1993; 72: 821-822.
25. Gold R, Comi G, Palace J, et al. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol 2014; 261: 267-276.
26. FDA, US Food and Drug Administration. Gilenya (fingolimod) capsules prescribing information, May 2015. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm266123.htm (. accessed 24 August 2015).
27. Huikuri HV, Pikkujämsä SM, Airaksinen KE, et al. Sex-related differences in autonomic modulation of heart rate in middle-aged subjects. Circulation 1996; 94: 122-125.
28. Umetani K, Singer DH, McCraty R, et al. Twenty-four hour time domain heart rate variability and heart rate: relations to age and gender over nine decades. J Am Coll Cardiol 1998; 31: 593-601.